LUGPA Policy Brief: UnitedHealthcare’s 2026 Medicare Advantage Referral Requirements – A Barrier to Timely Urologic CareMarch 2026 At-a-Glance Essentials What’s Changing Why It Matters LUGPA’s Position What We’re Calling For Policy Overview Beginning January 1, 2026, most members in UHC Medicare Advantage HMO and HMO-POS plans must obtain a PCP referral before seeing certain outpatient specialists. Key Provisions:
Specialties Exempt from Referral Requirements Include: Notably, urology is not exempt. Reports from member practices indicate referrals may require renewal every six months, with defined service dates and visit limits. Separately, UHC plans to implement prior authorization requirements for certain outpatient chemotherapy services beginning June 1, 2026. Impact on Urologic Care LUGPA member practices deliver high-volume, integrated care for prostate, bladder, and kidney cancers—often serving as the entry point into the oncology care pathway. 1. Delays in Diagnosis and Treatment Prostate cancer evaluation frequently begins in urology, including biopsy and surgical management. Requiring PCP referrals introduces additional administrative steps that may delay definitive care, even when oncology specialists are exempt. 2. Disruption of Ongoing Therapy Bladder cancer treatments such as intravesical BCG therapy follow strict schedules. Referral expirations mid-treatment risk interruptions that could compromise outcomes. 3. Increased Administrative Burden and Financial Risk Practices must track referral status, duration, and visit counts. Because denials are provider liability, the financial burden falls directly on independent urology groups. 4. Layered Gatekeeping Combined with existing prior authorization requirements and new chemotherapy prior authorization policies, this creates compounded access barriers within oncology care pathways. These impacts disproportionately affect independent urology practices that serve large Medicare Advantage populations. Why LUGPA Opposes This Policy LUGPA has consistently opposed excessive utilization management policies that delay medically necessary care. In our formal letter to UnitedHealthcare, we emphasized that:
Policies that insert avoidable barriers between patients and specialists, particularly in oncology, undermine value-based care and patient-centered delivery models. LUGPA Recommendations 1. Immediate Targeted Exemptions UHC should exempt urology from referral requirements when services are related to cancer diagnosis or treatment, aligning policy with existing oncology exemptions. 2. Extend Referral Validity If referrals remain required, validity periods should be extended to cover a full course of treatment or, at a minimum, one year to prevent mid-treatment lapses. 3. Broader Medicare Advantage Reform Congress should advance reforms to reduce utilization management burdens in Medicare Advantage, including expansion of the Improving Seniors’ Timely Access to Care Act and related measures. 4. Ongoing Advocacy LUGPA encourages members to document disruptions in patient care and administrative burdens. These real-world examples strengthen advocacy with insurers and policymakers. Conclusion Independent urology practices play a central role in the diagnosis and treatment of urologic cancers. Policies that impose new administrative gatekeeping requirements—without meaningful clinical justification- risk delaying care, increasing financial strain, and undermining patient outcomes. LUGPA remains committed to engaging directly with UnitedHealthcare and congressional stakeholders to ensure Medicare Advantage policies support, rather than hinder, timely access to high-quality urologic care.
|
Announcements
Introducing LUGPALearn: Explore. Learn. Earn CME.
Learn how to have your facility become a SRC/NAFC Center of Excellence In Continence Care for Women.
LUGPA groups will receive a discount on certification fees.
LUGPA members can login to access past content On Demand.